Safety, tolerability and effectiveness of TMC207 in combination with an individualized background regimen in MDR-TB (Multi-drug Resistant Tuberculosis)

Mise à jour : Il y a 5 ans
Référence : EUCTR2008-008444-25

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

− To evaluate safety, tolerability, and efficacy of TMC207 as part of a multi-drug regimen in the treatment of subjects with MDR-TB; − To evaluate the pharmacokinetics of TMC207 and its primary metabolite M2, and pharmacokinetic/pharmacodynamic relationships for safety and efficacy. − To explore the effect of TMC207 on the experience of TB symptoms as measured by the Tuberculosis Symptoms Profile (TSP), and to explore the measurement properties of the TSP.


Critère d'inclusion

  • Sputum smear-positive pulmonary multi-drug resistant tuberculosis